Hyperlipemia
Conditions
Interventions
Experimental group:xuezhitong capsule
Control group:xuezhikang capsule
Placebo group:placebo
Sponsors
Dongfang Hospital of Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. conform to the diagnostic criteria of Western medicine for hypertriglyceridemia and TG 2.3 to 5.6 mmol/L 2. LDL-C<4.9mmol/L (190mg/dl) or TC<7.2mmol/L; 3. aged 18-80 years old male and female; 4. fasting blood glucose (FBG), conform to the diagnostic criteria for hypertriglyceridemia,Introducing TLC intervention for 2 weeks (Maintain a balanced diet and lifestyle during the period, and Discontinue all drugs that affect blood lipids) finish fasting blood lipids still met the above diagnostic criteria were reexamined after the introduction period; 5. The total score of dietary evaluation is less than or equal to 3 points; 6. The patient's informed consent and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Secondary hyperlipidemia (such as nephrotic syndrome hypothyroidismliver disease renal failur) caused by systemic diseases; Patients with secondary hyperlipidemia or homozygotic hypercholesterolemia caused by drugs (adrenal cortical steroid and contraceptives); 2. acute coronary syndromes acute cerebral vascular disease diabetics with poor blood sugar control grade III hypertension; 3. Patients with peripheral atherosclerotic disease and arterial stenosis > 70%; 4. Complicated with other serious primary diseases of heart, brain, lung, liver, kidney and hematopoietic system;serum CR>Normal Value; 5. Patients with allergies or allergic constitutions to known components of test or control drugs;ALT and/or AST= 1.5 times the normal upper limit BUN > normal upper limit of 1.2 times; 6. malignant tumor long-term alcoholism drug dependence mentally ill person; 7. pregnancy lactating women or men and women with recent family planning; 8. Participants who have participated in or are participating in other clinical trials within the last month; 9. Those who have been judged by the researcher to be unfit for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change rate of TG; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change rate of HDL-C;Change rate of LDL-C;Change rate of TC;success rate of control in hypercholesterolemia;Therapeutic effect of TCM syndromes;Therapeutic effect of single symptom of TCM;fasting blood sugar;uric acid; | — |
Countries
China
Contacts
Public ContactLiang Wei
Jilin Province Oriental Pharmacetical Co.,Ltd
Outcome results
None listed